Timing of de novo vaccination during pregnancy impacts maternal and newborn immunity

Maternal immunity is essential for protecting both the pregnant individual and fetus, balancing immune tolerance with defense against infection. While maternal vaccination enhances protection, the impact of gestational timing on antibody responses and transplacental antibody transfer remains unclear. The COVID-19 pandemic provided a unique opportunity to study primary SARS-CoV-2 vaccine-induced humoral responses in individuals without documented prior SARS-CoV-2 infection or vaccination. To investigate how vaccination timing shapes maternal and fetal immunity, we performed comprehensive serological profiling in 263 individuals, including 96 maternal–neonatal dyads, sampled across pregnancy and at delivery. Leveraging natural variation in SARS-CoV-2 vaccine timing, we assessed antibody responses to SARS-CoV-2 and 13 additional pathogens using Systems Serology, analyzing isotypes, subclasses, FcγR binding, glycosylation, neutralization, and Fc-mediated functions. Pregnant individuals maintained stable immunity to previously encountered antigens (from past infections or vaccinations) and mounted expected responses to pertussis and tetanus boosters. Initial responses to COVID-19 mRNA vaccination were attenuated in third-trimester vaccinees but reached comparable levels after the second dose. Enhanced responses to unrelated antigens, such as poliovirus and measles, were observed, particularly in later gestation, potentially due to cross-reactivity. Antibody transfer was most efficient following late second to early third trimester vaccination, with decreased transfer in the late third trimester. Fetal sex also influenced antibody transfer efficiency, favoring male fetuses in the third trimester. These findings underscore the importance of vaccine timing to optimize maternal and neonatal immunity.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-17
DOI
https://doi.org/10.1038/s41598-026-80897-0
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Timing of de novo vaccination during pregnancy impacts maternal and newborn immunity

Andrea G. Edlow, Paola A. Lopez, Nadège Nziza, Michal A. Elovitz et al.
Scientific Reports
SARS-CoV-2 and COVID-19 Research
article

Timing of de novo vaccination during pregnancy impacts maternal and newborn immunity

Andrea G. Edlow, Paola A. Lopez, Nadège Nziza, Michal A. Elovitz, Galit Alter, Shlomi Ilan, Douglas A. Lauffenburger, Vicky Roy, Alejandro Benjamin Balazs, Olyvia J. Jasset, Tina Chen, Boris Dominik Jülg, Laura C. Ibanez-Pintor, Rachel Yinger, Sarah Lawler, Yi Cao, Benjamin Kellman, Agness Lakudzala
article en

Abstract

Maternal immunity is essential for protecting both the pregnant individual and fetus, balancing immune tolerance with defense against infection. While maternal vaccination enhances protection, the impact of gestational timing on antibody responses and transplacental antibody transfer remains unclear. The COVID-19 pandemic provided a unique opportunity to study primary SARS-CoV-2 vaccine-induced humoral responses in individuals without documented prior SARS-CoV-2 infection or vaccination. To investigate how vaccination timing shapes maternal and fetal immunity, we performed comprehensive serological profiling in 263 individuals, including 96 maternal–neonatal dyads, sampled across pregnancy and at delivery. Leveraging natural variation in SARS-CoV-2 vaccine timing, we assessed antibody responses to SARS-CoV-2 and 13 additional pathogens using Systems Serology, analyzing isotypes, subclasses, FcγR binding, glycosylation, neutralization, and Fc-mediated functions. Pregnant individuals maintained stable immunity to previously encountered antigens (from past infections or vaccinations) and mounted expected responses to pertussis and tetanus boosters. Initial responses to COVID-19 mRNA vaccination were attenuated in third-trimester vaccinees but reached comparable levels after the second dose. Enhanced responses to unrelated antigens, such as poliovirus and measles, were observed, particularly in later gestation, potentially due to cross-reactivity. Antibody transfer was most efficient following late second to early third trimester vaccination, with decreased transfer in the late third trimester. Fetal sex also influenced antibody transfer efficiency, favoring male fetuses in the third trimester. These findings underscore the importance of vaccine timing to optimize maternal and neonatal immunity.

Scientific Reports
Harvard University (US), University of Malawi (MW), Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MW), Ragon Institute of MGH, MIT and Harvard (US), Massachusetts General Hospital (US), Massachusetts Institute of Technology (US)
Massachusetts General Hospital, Ragon Institute of MGH, MIT and Harvard, Coalition for Epidemic Preparedness Innovations, Centers for Disease Control and Prevention Foundation, National Institutes of Health, Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon